NO20071515L - Lerkanidipinsalt - Google Patents

Lerkanidipinsalt

Info

Publication number
NO20071515L
NO20071515L NO20071515A NO20071515A NO20071515L NO 20071515 L NO20071515 L NO 20071515L NO 20071515 A NO20071515 A NO 20071515A NO 20071515 A NO20071515 A NO 20071515A NO 20071515 L NO20071515 L NO 20071515L
Authority
NO
Norway
Prior art keywords
acids
clerididipine
acidic
amorphous
salts
Prior art date
Application number
NO20071515A
Other languages
English (en)
Norwegian (no)
Inventor
Gianni Motta
Amadeo Leonardi
Markus Von Raumer
Original Assignee
Recordati Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recordati Ireland Ltd filed Critical Recordati Ireland Ltd
Publication of NO20071515L publication Critical patent/NO20071515L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
NO20071515A 2004-08-24 2007-03-23 Lerkanidipinsalt NO20071515L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60414904P 2004-08-24 2004-08-24
PCT/EP2005/009043 WO2006021397A1 (en) 2004-08-24 2005-08-22 Lercanidipine salts

Publications (1)

Publication Number Publication Date
NO20071515L true NO20071515L (no) 2007-05-22

Family

ID=35159792

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20071515A NO20071515L (no) 2004-08-24 2007-03-23 Lerkanidipinsalt

Country Status (19)

Country Link
US (1) US7683179B2 (pt)
EP (1) EP1799644B1 (pt)
JP (1) JP2008510754A (pt)
KR (1) KR20070045351A (pt)
CN (1) CN101048379A (pt)
AR (1) AR050467A1 (pt)
AU (1) AU2005276619B2 (pt)
BR (1) BRPI0514606A (pt)
CA (1) CA2575078A1 (pt)
EA (1) EA011773B1 (pt)
ES (1) ES2462921T3 (pt)
IL (1) IL180905A0 (pt)
MX (1) MX2007002141A (pt)
NO (1) NO20071515L (pt)
NZ (1) NZ553127A (pt)
PE (1) PE20060629A1 (pt)
TW (1) TW200613275A (pt)
WO (1) WO2006021397A1 (pt)
ZA (1) ZA200702364B (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS50955B (sr) * 2001-02-24 2010-08-31 Boehringer Ingelheim Pharma Gmbh. & Co.Kg. Derivati ksantina, njihovo dobijanje i njihova primena kao lekova
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
AR052918A1 (es) * 2005-02-25 2007-04-11 Recordati Ireland Ltd Clorhidrato de lercanidipina amorfo
AR053023A1 (es) * 2005-02-25 2007-04-18 Recordati Ireland Ltd Base libre de lercanidipina, metodos para su preparacion y composiciones farmaceuticas que las contienen
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
NZ619413A (en) 2006-05-04 2015-08-28 Boehringer Ingelheim Int Polymorphs of a dpp-iv enzyme inhibitor
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
AU2007257882B2 (en) 2006-06-12 2011-09-08 Secura Bio Inc. Process for making salts of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide
WO2008040367A1 (en) * 2006-08-01 2008-04-10 Union Quimico-Farmaceutica S.A. Lercanidipine hydrobromide, a process for its preparation, crystalline forms and compositions thereof
US20080175872A1 (en) * 2006-09-28 2008-07-24 Osmotica Corp. Controlled Release Dosage Form Containing Lercanidipine and a Performance-enhancing Acid
ES2306595B1 (es) * 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
IN2009DN05509A (pt) * 2007-03-14 2010-04-30 Teva Pharma
WO2009017813A1 (en) * 2007-08-02 2009-02-05 Teva Pharmaceutical Industries Ltd. O-desmethyl venlafaxine saccharinate
CA2706775A1 (en) 2007-11-26 2009-06-04 Teva Pharmaceutical Industries Ltd. Crystal forms of o-desmethylvenlafaxine fumarate
AR071175A1 (es) 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
AU2009277100B2 (en) * 2008-08-01 2015-05-28 Chiesi Farmaceutici S.P.A. Pharmaceutical compositions and methods for stabilizing the same
AU2009276560B2 (en) * 2008-08-01 2015-04-16 Chiesi Farmaceutici S.P.A. Pharmaceutical compositions and methods for producing low impurity concentrations of the same
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0919288A2 (pt) 2008-09-10 2015-12-15 Boehring Ingelheim Internat Gmbh teriapia de combinação para tratamento de diabetes e condições relacionadas.
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CN102256976A (zh) 2008-12-23 2011-11-23 贝林格尔.英格海姆国际有限公司 有机化合物的盐形式
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
KR20210033559A (ko) 2009-11-27 2021-03-26 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 dpp-iv 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
KR101409554B1 (ko) * 2010-03-29 2014-06-19 플리바 흐르바츠카 디.오.오. O-데스메틸벤라팍신 푸마레이트의 결정형
CN102946875A (zh) 2010-05-05 2013-02-27 贝林格尔.英格海姆国际有限公司 组合疗法
EP3124041A1 (en) 2010-06-24 2017-02-01 Boehringer Ingelheim International GmbH Diabetes therapy
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
AU2012285904C1 (en) 2011-07-15 2017-08-31 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
WO2023219106A1 (ja) * 2022-05-10 2023-11-16 Myrodia Therapeutics株式会社 2-メチル-2-チアゾリンの塩

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8403866D0 (en) 1984-02-14 1984-03-21 Recordati Chem Pharm Diphenylalkylaminoalkyl esters
US5696139A (en) 1995-05-12 1997-12-09 Recordati S.A., Chemical And Pharmaceutical Company Use of S-enantiomers of 1,4-dihydropyridine derivatives for treating heart failure
US5767136A (en) 1995-05-12 1998-06-16 Recordati, S.A. Chemical And Pharmaceutical Company 1,4-Dihydropyridines useful for prevention or reduction of atherosclerotic lesions on arterial walls
IT1275532B (it) * 1995-07-14 1997-08-07 Recordati Chem Pharm Uso di derivati 1,4-diidropiridinici per la prevenzione e la terapia della degenerazione aterosclerotica della parete arteriosa
IT1301759B1 (it) * 1998-06-19 2000-07-07 Nicox Sa Sali nitrati di farmaci antiipertensivi
US20030069285A1 (en) 2001-08-06 2003-04-10 Recordati Ireland Limited Novel solvate and crystalline forms of lercanidipine hydrochloride
US6852737B2 (en) 2001-08-06 2005-02-08 Recordati Ireland Limited Crude and crystalline forms of lercanidipine hydrochloride
US6699892B2 (en) * 2002-06-04 2004-03-02 Yung Shin Pharmaceutical Industrial Co., Ltd. Pharmaceutically acceptable salt of amlodipine and method of preparing the same
EP1553941A1 (en) * 2002-10-16 2005-07-20 Recordati Ireland Limited Lisinopril/lercanidipine combination therapy
US20040198789A1 (en) * 2003-02-28 2004-10-07 Recordati Ireland Limited Lercanidipine/ARB/diuretic therapeutic combinations

Also Published As

Publication number Publication date
US7683179B2 (en) 2010-03-23
AU2005276619B2 (en) 2009-04-30
ES2462921T3 (es) 2014-05-26
NZ553127A (en) 2009-07-31
EA011773B1 (ru) 2009-06-30
EP1799644A1 (en) 2007-06-27
WO2006021397A1 (en) 2006-03-02
EP1799644B1 (en) 2014-02-12
TW200613275A (en) 2006-05-01
IL180905A0 (en) 2007-07-04
MX2007002141A (es) 2007-04-27
US20060047125A1 (en) 2006-03-02
AU2005276619A1 (en) 2006-03-02
KR20070045351A (ko) 2007-05-02
AR050467A1 (es) 2006-10-25
BRPI0514606A (pt) 2008-06-17
WO2006021397A8 (en) 2006-04-27
ZA200702364B (en) 2008-09-25
PE20060629A1 (es) 2006-08-11
JP2008510754A (ja) 2008-04-10
CA2575078A1 (en) 2006-03-02
CN101048379A (zh) 2007-10-03
EA200700492A1 (ru) 2007-08-31

Similar Documents

Publication Publication Date Title
NO20071515L (no) Lerkanidipinsalt
NO20073720L (no) Heterocyklisk substituerte fenylmetanoner som inhibitorer av glycintransportorer
NO20092762L (no) 2-aza-bicyklo[3.1.0]heksanderivater
CY1113029T1 (el) Παραγωγα αζαδικυκλο [3.1.0] εξανιου χρησιμα ως ρυθμιστες υποδοχεων d3 ντοπαμινης
NO20083358L (no) Piperasinyl derivater som modulatorer for kjemokine reseptor aktivitet
CL2010000204A1 (es) Compuestos intermediarios derivados de 4 amino-3-metoxibenzamida; compuesto intermediario n-{4-[4-(ciclopropilmetil)piperazin-1-il]ciclohexil}acetamida; compuesto intermediario 2-cloro-7-etil-7,8-dihidro-5-metil-8-(1-metiletil)-6(5h)-pteridinona, útiles en la preparación de dihidropteridinonas sustituidas (divisional sol. 2077-05).
NO20063748L (no) Kinolinderivater og anvendelse derav som mykobakterielle inhibitorer
NO20092770L (no) Nye aminopyrimidinderivater som PLK1-inhibitorer
NO20083582L (no) Pyridin-2-karboksamide derivater
MX367154B (es) Formas solidas de acido 3-(6-(1-(2,2-difluorobenzo[d] [1,3]dioxol-5-il)ciclopropancarboxamido)-3-metilpiridin-2-il)benz oico.
PE20081846A1 (es) Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico
CY1114303T1 (el) Νεο οξινο θειικο αλας
PE20070164A1 (es) Compuestos triazolopiridinas como inhibidores de la 11-beta hidroxiesteroide deshidrogenasa tipo i
NO20080052L (no) G-Protein kopplede reseptoragonister
EA201201033A1 (ru) Циклический амин и акарицид
CA2478237A1 (en) Use of adapalene for the treatment of dermatological disorders
NO20083708L (no) 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer
HK1116492A1 (en) Method for the production of 5-(4-[4-(5-cyano-3-indolyl)-butyl]-1- piperazinyl)-benzofuran-2-carboxamide
GEP20084494B (en) New heterocyclic carboxylic acid amide derivatives
EA200000804A1 (ru) Мета-азациклические соединения аминобензойной кислоты и их производные, являющиеся ингибиторами интегрина
NO20091782L (no) Fremgangsmate for syntese av derivater av 3-amino-tetrahydrofuran-3-karboxylsyre og deres anvendelse som medikamenter
DE602006013136D1 (de) Ermediate
NO20092528L (no) Krystallinske kaliumsalter av lipoksin A4-analoger
NO20071111L (no) Kynurensyreamidderivater som NR2B-reseptorantagonister
NO20080457L (no) Kjemiske forbindelser

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application